IFG Advisory LLC grew its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 3.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,176 shares of the pharmaceutical company’s stock after purchasing an additional 422 shares during the quarter. IFG Advisory LLC’s holdings in GlaxoSmithKline were worth $592,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Wealthcare Advisory Partners LLC increased its holdings in GlaxoSmithKline by 6.6% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 4,020 shares of the pharmaceutical company’s stock worth $154,000 after acquiring an additional 249 shares during the last quarter. 1832 Asset Management L.P. increased its holdings in GlaxoSmithKline by 35.2% in the 4th quarter. 1832 Asset Management L.P. now owns 967 shares of the pharmaceutical company’s stock worth $37,000 after acquiring an additional 252 shares during the last quarter. Reilly Financial Advisors LLC increased its holdings in GlaxoSmithKline by 36.7% in the 1st quarter. Reilly Financial Advisors LLC now owns 950 shares of the pharmaceutical company’s stock worth $36,000 after acquiring an additional 255 shares during the last quarter. Courier Capital LLC increased its holdings in GlaxoSmithKline by 3.0% in the 4th quarter. Courier Capital LLC now owns 9,025 shares of the pharmaceutical company’s stock worth $345,000 after acquiring an additional 260 shares during the last quarter. Finally, grace capital increased its holdings in GlaxoSmithKline by 2.7% in the 4th quarter. grace capital now owns 9,833 shares of the pharmaceutical company’s stock worth $376,000 after acquiring an additional 263 shares during the last quarter. 11.31% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts recently weighed in on GSK shares. UBS Group lowered GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Friday, February 22nd. Shore Capital lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Finally, Zacks Investment Research upgraded GlaxoSmithKline from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $41.83.
Shares of NYSE GSK opened at $39.99 on Friday. GlaxoSmithKline plc has a 52 week low of $36.41 and a 52 week high of $42.36. The company has a quick ratio of 0.48, a current ratio of 0.72 and a debt-to-equity ratio of 6.92. The stock has a market capitalization of $97.71 billion, a price-to-earnings ratio of 12.66, a P/E/G ratio of 2.03 and a beta of 0.74.
GlaxoSmithKline (NYSE:GSK) last issued its earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.66 by $0.13. GlaxoSmithKline had a return on equity of 171.27% and a net margin of 12.27%. The business had revenue of $9.98 billion during the quarter, compared to the consensus estimate of $9.86 billion. On average, equities analysts forecast that GlaxoSmithKline plc will post 2.92 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a $0.4953 dividend. The ex-dividend date is Thursday, May 16th. This represents a $1.98 annualized dividend and a yield of 4.95%. GlaxoSmithKline’s dividend payout ratio is currently 61.71%.
In other GlaxoSmithKline news, Director Plc Glaxosmithkline purchased 325,000 shares of the company’s stock in a transaction dated Monday, April 22nd. The stock was purchased at an average price of $18.00 per share, for a total transaction of $5,850,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.00% of the stock is owned by company insiders.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: Stock Symbols and CUSIP Explained
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.